Lymphoproliferative Disorder Treatment Market - Top Companies and Manufacturers

Companies Dominating the Lymphoproliferative Disorder Treatment Landscape

Atara Biotherapeutics, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

Merck & Co., Inc.
Bristol Myers Squibb Company
Genentech, Inc.
ADC Therapeutics SA
AbbVie Inc.
Novartis AG
Pfizer Inc.
AstraZeneca
Gilead Sciences, Inc.

Browse Key Market Insights with Data Illustration:

Lymphoproliferative Disorder Treatment Market Outlook 2024-2036

In the News

ADC Therapeutics SA disclosed its Phase 2 clinical trial findings for camidanlumab tesirine (Cami) in relapsed or refractory (r/r) Hodgkin lymphoma. Cami has been examined in a key Phase 2 clinical trial in individuals who have relapsed or refractory Hodgkin lymphoma, as well as a Phase 1b clinical trial in tumor cells as monotherapy and in combination with pembrolizumab.
Genentech, Inc. has announced that the FDA has granted approval for Lunsumio (mosunetuzumab-axgb) for the treatment of adult individuals who have relapsed or refractory (R/R) follicular lymphoma (FL) following two or more lines of systemic therapy. This indication has been granted rapid approval based on the response rate.

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of lymphoproliferative disorder treatment is assessed at USD 5.65 Billion.

The lymphoproliferative disorder treatment market size was over USD 5.33 Billion in 2023 and is expected to reach USD 12.23 Billion by the end of 2036, witnessing around 6.6% CAGR during the forecast period i.e., between 2024-2036. Worldwide expanding prevalence of lymphoma cases, rise in the cases of chronic lymphocytic leukemia (CLL), and an upsurge in novel targeted treatments are the major factors driving the market growth.

North America is likely to dominate majority industry share of about 45% by 2036, propelled by increasing frequency of the lymphoproliferative disorder in the region along with an increase in focus on research and development for the effective treatment of such disorders.

Atara Biotherapeutics, Inc., Merck & Co., Inc., Bristol Myers Squibb Company, Genentech, Inc., ADC Therapeutics SA, AbbVie Inc., Novartis AG, Pfizer Inc., AstraZeneca, Gilead Sciences, Inc.

Lymphoproliferative Disorder Treatment Market - Top Companies and Manufacturers

Companies Dominating the Lymphoproliferative Disorder Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How much is the lymphoproliferative disorder treatment market worth?

Why is the demand for lymphoproliferative disorder treatment growing?

Which region dominated the majority of lymphoproliferative disorder treatment industry share?

Who are the top lymphoproliferative disorder treatment companies?